Vistagen Therapeutics (NASDAQ:VTGN) Stock In Breakout: How to Trade Now?
Biopharmaceutical company Vistagen Therapeutics (NASDAQ:VTGN), engaged in new generation of medicines having potential of going beyond standard current care for nervous system disorders, has confirmed appointment of Mary L. Rotunno, J.D. to the Board of Directors.
Shawn Singh, Chief Executive Officer of VistaGen, appreciated Mary’s experience of over three decades in leadership commencing with serving patients as a nurse and moving to serving clients in health care law. He added on Rotunno’s distinguished track record for advocating both healthcare providers and patients to provide valuable insights for value-based care.
Ms Rotunno is also a trusted advisor on regulatory, complex governance and compliance requirements for a number of firms, according to Singh. She is also serving General Counsel and Member of Executive Leadership Team at a $ 1 billion revenue health care system, El Camino Health. Ms Rotunno has also served over 11 years as Senior Counsel and Client Service Leader for Common Spirit Health in San Francisco Bay Area.
Graduating from University of Illinois having a Bachelor of Science in Nursing, she has worked as registered nurse before earning her Juris Doctor degree. Obtaining certification by the Women’s Corporate Board Readiness Program at Santa Clara University, she was with Hastings Leadership Academy for Women and Dignity Health Ministry Leadership Program.
Market Reaction:
On Thursday, VTGN stock fell 2% at $3.15 with more than 1.82 million shares, compared to its average volume of 2.96 million shares. The stock had moved within a range of $3.0800 – 3.2400 after opening the trade at $3.09. Over the past 52-week, the stock has been trading within a range of $0.4600 – 3.5500.
